124956-29-2

Upstream product

• 134-96-3 syringic aldehyde 
• 101620-00-2 (2E,4E)-5-(3,5-dimethoxy-4-(2-methoxyethoxy)methoxyphenyl)-2,4-pentadienoic acid ethyl ester 
• 17403-09-7 3-(4-piperidinyl)-1H-indole 
• 57311-67-8 4-(1H-indol-3-yl)-1-piperidineethanamine 
• 101620-01-3 (2E,4E)-5-(3,5-dimethoxy-4-(2-methoxyethoxy)methoxyphenyl)-2,4-pentadienoic acid 
• 101641-07-0 3,5-dimethoxy-4-((2-methoxyethoxy)methoxy)benzaldehyde 
• 57311-64-5 N-(2-(4-(1H-indol-3-yl)piperidin-1-yl)ethyl)phthalimide 

Downstream Products

• 124956-36-1 (2E,4E)-5-(3,5-dimethoxy-4-hydroxyphenyl)-N-(2-(4-(1H-indol-3-yl)piperidin-1-yl)ethyl)-2,4-pentadienamide 

Relevant academic research and scientific papers

(2E,4E)-N-(4-(1H-indol-3-yl)piperidin-1-yl)alkyl-5-(substituted phenyl)-2,4-pentadienamides as antiallergic agents with antihistaminic and anti slow-reacting substance (SRS) activities

As an extension of our study aiming to discover a novel compound with dual activities against histamine and slow-reacting substance (SRS), we synthesized two types of indolylpiperidine derivatives, 3 and 4-20. Testing for in vivo antianaphylactic activity and for in vitro anti-SRS activity revealed that (2E,4E)-5-(3,5-dimethoxy-4-hydroxyphenyl)-N-(2-(4-(1H-indol-3-yl)piper idin-1-yl)ethyl)-2,4-pentadienamide (11) exhibited potent dual activities with ED50 = 0.89 mg/kg and IC50 = 1.43 μM, respectively. However, the plasma concentration of unchanged 11 was very low when administered orally in guinea pigs. This result can be explained by fast formation of a glucuronic acid conjugate.